stockrow
Monday 9 November 2026
Export PRQR’s income statement to Excel — free account
ProQR Therapeutics N.V.
PRQRProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024.
- Revenue
- +135.0%
- EPS
- +28.6%
- Free cash flow
- −1.06%
- Total debt
- +8.71%
Quarter to June 2026, against a year earlier
1.35
0.02
+1.50%
Follow PRQR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 1 | 1 | 2 |
+8 more TTM periods Free account |
| (58.29%) | (83.00%) | (62.93%) | (100.28%) | ||
| (31.53%) | (38.28%) | (30.86%) | (35.93%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.79%) | (70.48%) | (52.52%) | (44.29%) | |
Average Days of Receivables |
77.26 | 120.49 | 156.04 | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.54) | (0.58) | (0.54) | |
Free Cash Flow |
(57.39) | (57.24) | (60.88) | (56.44) | |
Capital Expenditures |
(1.31) | (1.11) | (1.15) | (0.70) | |
| Other line items | |||||
Cash ROIC |
(24.48%) | (39.56%) | (36.69%) | (28.61%) | |
Accounts Receivable Turnover |
8.62 | 5.53 | 0.52 | 0.00 | |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
248.08% | 329.65% | 281.23% | 294.06% | |
Selling, General and Administrative Expense of Revenue |
85.66% | 116.17% | 94.68% | 97.82% | |
Share Based Compensation of Revenue |
27.43% | 34.67% | 25.24% | 22.46% | |
Operating CF/Net income |
1.14 | 1.06 | 1.25 | 1.18 | |
Depreciation/Fixed assets |
0.23 | 0.22 | 0.21 | 0.20 | |
Capex/Depreciation |
(0.42) | (0.35) | (0.38) | (0.23) | |
Revenue per Share |
0.20 | 0.15 | 0.17 | 0.16 | |
Operating CF per Share |
(0.51) | (0.53) | (0.57) | (0.53) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.06 | 0.07 | 0.06 | 0.04 |
Columns are period end dates